Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Wong, Ching Yee O ^a,b   Schmidt, Joseph ^b   Bong, Jeffery S ^b   Chundru, Suyra ^a   Kestin, Larry ^a   Yan, Di ^a   Grills, Inga ^a   Gaskill, Marianne ^a   Cheng, Vincent ^a   Martinez, Alvaro A ^a   Fink Bennett, Darlene ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; THEORETICAL MODEL; TIME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SMALL CELL LUNG CARCINOMA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34250858980     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-18     Document Type: Article

References (21)

1. Pöttgen C Levegrun S Theegarten D Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy Clin Cancer Res 2006 12 1 97-106 10.1158/1078-0432.CCR-05-0510 16397030
2. Hicks RJ Kalff V MacManus MP (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer J Nucl Med 2001 42 11 1596-604 11696627
3. Choi NC Fischman AJ Niemierko A Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2002 54 4 1024-35 10.1016/S0360-3016(02)03038-9 12419428
4. Huang SC Phelps ME Hoffman EJ Sideris K Selin CJ Kuhl DE Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980 238 E69-E82
5. Sokoloff L Reivich M Kennedy C Des Rosiers MH Patlak CS Pettigrew KD Sakurada O Shinohara M The [C-14]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat J Neuro Chem 1977 28 897-916
6. Langen KJ Braun U Rota Kops E The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas J Nucl Med 1993 34 355-359 8441023
7. Huang SC Anatomy of SUV Nucl Med Biol 2000 27 643-6 10.1016/ S0969-8051(00)00155-4 11091106
8. Young H Baum R Cremerius U Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations-European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 1999 35 1773-1782 10.1016/S0959-8049(99)00229-4 10673991
9. Therasse P Arbuck SG Eisenhauer EA New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 205-216 10.1093/jnci/92.3.205 10655437
10. Black QC Grills IS Kestin LL Wong CY Wong JW Martinez AA Yan D Defining a radiotherapy target with positron emission tomography Int J Radiat Oncol Biol Phys 60 4 1272-82 2004 Nov 15; 10.1016/j.ijrobp.2004.06.254 15519800
11. Grills IS Yan D Black QC Wong CY Martinez AA Kestin LL Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2007 67 3 709-19 17197120
12. Wong CY Salem R Raman S Gates VL Dworkin HJ Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: A comparison with CT or MRI Eur J Nucl Med Mol Imaging 2002 29 6 815-20 10.1007/s00259-002-0787-4 12029557
13. Hicks RJ Mac Manus MP Matthews JP Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation Int J Radiat Oncol Biol Phys 60 2 412-8 2004 Oct 1; 10.1016/j.ijrobp.2004.03.036 15380574
14. Hoekstra CJ Stroobants SG Smit EF Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer J Clin Oncol 2005 23 33 8362-70 10.1200/JCO.2005.01.1189 16293866
15. Eschmann SM Friedel G Paulsen F Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer Lung Cancer 2007 55 2 165-71 10.1016/j.lungcan.2006.09.028 17129635
16. Spaepen K Stroobants S Dupont P Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001 19 414-419 11208833
17. Jerusalem G Beguin Y Fassotte MF Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging Blood 1999 94 429-433 10397709
18. Weihrauch MR Re D Scheidhauer K Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease Blood 2001 98 2930-2934 10.1182/blood.V98.10.2930 11698273
19. Mikhaeel NG Timothy AR O'Doherty MJ Hain S Maisey MN 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma: Comparison with CT Leuk Lymphoma 2000 39 543-553 11342337
20. Kostakoglu L Coleman M Leonard JP Kuji I Zoe H Goldsmith SJ PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease J Nucl Med 2002 43 1018-1027 12163626
21. Spaepen K Stroobants S Dupont P Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 2002 13 9 1356-63 10.1093/annonc/mdf256 12196360